

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

ELECTION OF LANGUAGE AND MEANS OF RECEIPT OF CORPORATE COMMUNICATIONS

The Company will make arrangements to ascertain the preferences of the Shareholders with respect to the election of language(s) and/or the means of receipt of its Corporate Communication in accordance with Rules 2.07A and 2.07B of the Listing Rules and the Company's articles of association.

INTRODUCTION

In order to increase efficiency in communication with the Shareholders and to contribute to environmental protection and for the purpose of saving printing and mailing costs, the Company is making arrangements to ascertain how the Shareholders wish to receive future Corporate Communication from the Company: (i) by electronic means through the Company's website at www.purapharm.com.hk and to receive a notification letter whenever the Company's future Corporate Communication is published on the Company's website; or (ii) in printed form, in English language version only, in Chinese language version only, or in both English and Chinese language versions.

ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules, the following arrangements have been made by the Company:

1. The letter dated 5 July 2021 (the “**First Letter**”) will be sent by the Company together with the Reply Form, in both English and Chinese versions, to the Shareholders to enable them to elect for any one of the following options:
 - (i) to read the Website Version of all future Corporate Communications instead of receiving printed copies, and to receive a printed notification letter of the publication of the Corporate Communications on the Company’s website by post; or
 - (ii) to receive the printed English version of all future Corporate Communications by post only; or
 - (iii) to receive the printed Chinese version of all future Corporate Communications by post only; or
 - (iv) to receive both the printed English and Chinese versions of all future Corporate Communications by post.

The Reply Form should be completed, signed and returned by post using the mailing label at the bottom of the Reply Form or by hand delivery to the Company c/o the Hong Kong Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, on or before 4 August 2021.

The First Letter explains that if the Company does not receive the Reply Form or a response indicating any objection from the Shareholder on or before 4 August 2021 and until the Shareholder informs the Company c/o the Hong Kong Share Registrar by reasonable prior notice in writing or by sending an email to purapharm.ecom@computershare.com.hk, such Shareholder will be deemed to have consented to receive the Website Version, and a notification letter of the publication of the Corporate Communications on the Company’s website will be sent to such Shareholder in the future.

2. For Shareholders who/which choose to receive Corporate Communication in printed form, the Company will send the selected language version(s) of the Corporate Communication to them unless and until they notify the Hong Kong Share Registrar in writing or by email to purapharm.ecom@computershare.com.hk that they wish to receive the Corporate Communication in the other (or both) language(s), or by electronic means through the Company’s website.

3. For Shareholders who/which choose (or are deemed to have consented) to receive Corporate Communication by electronic means through the Company's website, the Company will send a notification letter of the publication of the Corporate Communication on the Company's website to such Shareholder by post at his/her/its address as appearing on the Company's register of members maintained by the Hong Kong Share Registrar.
4. When each printed Corporate Communication is sent out by the Company in accordance with the arrangements described in paragraph 2 above, a letter (the "**Notification Letter**") and a change request form (the "**Change Request Form**") will be attached to or printed in the relevant Corporate Communication, specifying that the Corporate Communication prepared in the other language will be available upon request, and such Shareholders may change their choice of language(s) and/or the means of receipt of the Corporate Communication by completing and returning the Change Request Form to the Hong Kong Share Registrar by post, by hand or via email to purapharm.ecom@computershare.com.hk.
5. Shareholders are also entitled, at any time, by reasonable notice in writing to the Company c/o the Hong Kong Share Registrar to change the choice of language(s) and/or the means of receipt of Corporate Communication. Shareholders may also send such notice by email to purapharm.ecom@computershare.com.hk. With respect to Shareholders who/which have chosen (or are deemed to have consented) to receive Corporate Communication by electronic means but for any reason have difficulty in receiving or gaining access to the Corporate Communication, the Company will promptly, upon such Shareholders' request, send the Corporate Communication to such Shareholders in printed form free of charge.
6. All future Corporate Communications in both English and Chinese versions and in accessible format will be available on the Company's website at www.purapharm.com.hk and the Stock Exchange website at www.hkexnews.hk.
7. Shareholders shall have the right at any time by reasonable prior notice in writing to the Company c/o the Hong Kong Share Registrar or by sending a prior notice via email at purapharm.ecom@computershare.com.hk specifying their name, address and request, to change the means of receipt and/or the language of the Corporate Communications.
8. Shareholders can call the hotline of the Hong Kong Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding public holidays) in respect of any queries in relation to the Company's arrangements set out above.

9. The First Letter and the Notification Letter will state that both languages of Corporate Communication will be available on the Company’s website and the hotline service will be provided as described in this announcement.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the meanings set out below:

“Company”	PuraPharm Corporation Limited, a company incorporated in the Cayman Islands with limited liability, the Shares of which are listed on the Main Board of the Stock Exchange
“Corporate Communications”	documents issued or to be issued by the Company for the information or action of holders of any of the Company’s securities or the investing public as defined in Rule 1.01 of the Listing Rules, including but not limited to: (a) annual reports and its summary financial reports (where applicable) (and all reports and accounts contained therein); (b) the interim reports and its summary interim reports (where applicable)(and all reports and accounts contained therein); (c) notices of meeting; (d) listing documents; (e) circulars; and (f) proxy forms
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Hong Kong Share Registrar”	Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Reply Form”	a pre-paid reply form (a stamp is not needed for posting in Hong Kong) to be sent together with the First Letter
“Shareholder(s)”	Holder(s) of the shares of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

“Website Version”

the version of Corporate Communications published in electronic form, in both English and Chinese versions, on the Company’s website

By order of the Board
PuraPharm Corporation Limited
Mr. Chan Yu Ling, Abraham
Chairman and executive Director

Hong Kong, 5 July 2021

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors of the Company are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.